One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant

Hidehisa Kitada, Yasuhiro Okabe, Takehiro Nishiki, Yoshifumi Miura, Kei Kurihara, Soushi Terasaka, Sayako Kawanami, Akihiro Tuchimoto, Kohsuke Masutani, Masao Tanaka

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). We reviewed the 1-year outcomes of tacrolimus QD in de novo renal transplant. Materials and Methods: We reviewed 50 de novo renal transplant patients assigned in a nonrandomized fashion to either tacrolimus QD (n = 23, historic control group) or tacrolimus BID (n = 27). Other immunosuppressive drugs used in both groups included mycophenolate mofetil, basiliximab, and steroids. We evaluated trough levels, required dosages, renal function, rejection rates, and episodes of infection within 1 year after transplant. Results: Trough levels of both drugs varied during the perioperative periods, but subsequently stabilized in both groups. There was a tendency toward a slow elevation and a higher dosage requirement in the tacrolimus QD group, compared with the tacrolimus BID group in the early stages, though the required dosages decreased steadily. The rejection rate in the tacrolimus QD group was low, and only 1 patient experienced subclinical rejection. No severe infectious adverse events were observed. Conclusions: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus QD can be administered with excellent efficacy and safety in de novo renal transplant recipients.

Original languageEnglish
Pages (from-to)561-567
Number of pages7
JournalExperimental and Clinical Transplantation
Volume10
Issue number6
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Tacrolimus
Transplants
Kidney
Therapeutics
Mycophenolic Acid
Safety
Perioperative Period
Immunosuppressive Agents
Pharmaceutical Preparations
Steroids

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant. / Kitada, Hidehisa; Okabe, Yasuhiro; Nishiki, Takehiro; Miura, Yoshifumi; Kurihara, Kei; Terasaka, Soushi; Kawanami, Sayako; Tuchimoto, Akihiro; Masutani, Kohsuke; Tanaka, Masao.

In: Experimental and Clinical Transplantation, Vol. 10, No. 6, 01.12.2012, p. 561-567.

Research output: Contribution to journalArticle

Kitada, H, Okabe, Y, Nishiki, T, Miura, Y, Kurihara, K, Terasaka, S, Kawanami, S, Tuchimoto, A, Masutani, K & Tanaka, M 2012, 'One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant', Experimental and Clinical Transplantation, vol. 10, no. 6, pp. 561-567. https://doi.org/10.6002/ect.2012.0087
Kitada, Hidehisa ; Okabe, Yasuhiro ; Nishiki, Takehiro ; Miura, Yoshifumi ; Kurihara, Kei ; Terasaka, Soushi ; Kawanami, Sayako ; Tuchimoto, Akihiro ; Masutani, Kohsuke ; Tanaka, Masao. / One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant. In: Experimental and Clinical Transplantation. 2012 ; Vol. 10, No. 6. pp. 561-567.
@article{ffd0ab9bfd604997aa5c9e72156d1e15,
title = "One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant",
abstract = "Objectives: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). We reviewed the 1-year outcomes of tacrolimus QD in de novo renal transplant. Materials and Methods: We reviewed 50 de novo renal transplant patients assigned in a nonrandomized fashion to either tacrolimus QD (n = 23, historic control group) or tacrolimus BID (n = 27). Other immunosuppressive drugs used in both groups included mycophenolate mofetil, basiliximab, and steroids. We evaluated trough levels, required dosages, renal function, rejection rates, and episodes of infection within 1 year after transplant. Results: Trough levels of both drugs varied during the perioperative periods, but subsequently stabilized in both groups. There was a tendency toward a slow elevation and a higher dosage requirement in the tacrolimus QD group, compared with the tacrolimus BID group in the early stages, though the required dosages decreased steadily. The rejection rate in the tacrolimus QD group was low, and only 1 patient experienced subclinical rejection. No severe infectious adverse events were observed. Conclusions: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus QD can be administered with excellent efficacy and safety in de novo renal transplant recipients.",
author = "Hidehisa Kitada and Yasuhiro Okabe and Takehiro Nishiki and Yoshifumi Miura and Kei Kurihara and Soushi Terasaka and Sayako Kawanami and Akihiro Tuchimoto and Kohsuke Masutani and Masao Tanaka",
year = "2012",
month = "12",
day = "1",
doi = "10.6002/ect.2012.0087",
language = "English",
volume = "10",
pages = "561--567",
journal = "Experimental and Clinical Transplantation",
issn = "1304-0855",
publisher = "Baskent University",
number = "6",

}

TY - JOUR

T1 - One-year follow-up of treatment with once-daily tacrolimus in de novo renal transplant

AU - Kitada, Hidehisa

AU - Okabe, Yasuhiro

AU - Nishiki, Takehiro

AU - Miura, Yoshifumi

AU - Kurihara, Kei

AU - Terasaka, Soushi

AU - Kawanami, Sayako

AU - Tuchimoto, Akihiro

AU - Masutani, Kohsuke

AU - Tanaka, Masao

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Objectives: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). We reviewed the 1-year outcomes of tacrolimus QD in de novo renal transplant. Materials and Methods: We reviewed 50 de novo renal transplant patients assigned in a nonrandomized fashion to either tacrolimus QD (n = 23, historic control group) or tacrolimus BID (n = 27). Other immunosuppressive drugs used in both groups included mycophenolate mofetil, basiliximab, and steroids. We evaluated trough levels, required dosages, renal function, rejection rates, and episodes of infection within 1 year after transplant. Results: Trough levels of both drugs varied during the perioperative periods, but subsequently stabilized in both groups. There was a tendency toward a slow elevation and a higher dosage requirement in the tacrolimus QD group, compared with the tacrolimus BID group in the early stages, though the required dosages decreased steadily. The rejection rate in the tacrolimus QD group was low, and only 1 patient experienced subclinical rejection. No severe infectious adverse events were observed. Conclusions: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus QD can be administered with excellent efficacy and safety in de novo renal transplant recipients.

AB - Objectives: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). We reviewed the 1-year outcomes of tacrolimus QD in de novo renal transplant. Materials and Methods: We reviewed 50 de novo renal transplant patients assigned in a nonrandomized fashion to either tacrolimus QD (n = 23, historic control group) or tacrolimus BID (n = 27). Other immunosuppressive drugs used in both groups included mycophenolate mofetil, basiliximab, and steroids. We evaluated trough levels, required dosages, renal function, rejection rates, and episodes of infection within 1 year after transplant. Results: Trough levels of both drugs varied during the perioperative periods, but subsequently stabilized in both groups. There was a tendency toward a slow elevation and a higher dosage requirement in the tacrolimus QD group, compared with the tacrolimus BID group in the early stages, though the required dosages decreased steadily. The rejection rate in the tacrolimus QD group was low, and only 1 patient experienced subclinical rejection. No severe infectious adverse events were observed. Conclusions: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus QD can be administered with excellent efficacy and safety in de novo renal transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=84871318422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871318422&partnerID=8YFLogxK

U2 - 10.6002/ect.2012.0087

DO - 10.6002/ect.2012.0087

M3 - Article

C2 - 23082898

AN - SCOPUS:84871318422

VL - 10

SP - 561

EP - 567

JO - Experimental and Clinical Transplantation

JF - Experimental and Clinical Transplantation

SN - 1304-0855

IS - 6

ER -